Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CDH1 | P12830 | 1/20 | 0.33 |
| ▸ | TCF4 | P15884 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APC | P25054 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674308 | 0.79 | BRD9 (0.32) | TYK2 | |
| SCHEMBL2673740 | 0.72 | APOBEC3A (0.37) | KDM4ENPC1LMNAMAPTTSHR | |
| SCHEMBL2673093 | 0.70 | APOBEC3A (0.33) | — | |
| SCHEMBL5709766 | 0.69 | SMPD3 (0.38) | CYP3A4CYP2C9KDM4EALDH1A1HCRTR1 | |
| SCHEMBL2673207 | 0.69 | APOBEC3A (0.37) | CYP3A4KDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL2673255 | 0.69 | GRIK1 (0.40) | CYP3A4CYP2C9HTR2CKDM4ENPC1 | |
| SCHEMBL2673810 | 0.68 | HSD17B10 (0.40) | KDM4EALDH1A1TSHR | |
| SCHEMBL2672881 | 0.68 | APOBEC3A (0.38) | KDM4ENPC1ALDH1A1LMNATP53 | |
| SCHEMBL2674115 | 0.68 | APOBEC3A (0.47) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL2672868 | 0.68 | BRD4 (0.37) | KDM4EALDH1A1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213700-A1 | PREPARATION OF TERMINALLY UNSATURATED (METH)ACRYLATE CROSSLINKERS | RÖHM GMBH (DE) | 2023-11-09 | — | — | WO | disclosed |
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8173682-B2 | Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732446-A2 | METHODS AND DEVICES FOR IDENTIFYING TERRORISTS/CRIMINAL SUSPECTS BY DETECTING CONTACT OF HUMAN SKIN WITH RUBBER PROTECTIVE GEAR | THE JOHNS-HOPKINS UNIVERSITY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060084077-A1 | Methods and devices for identifying terrorists/criminal suspects by detecting contact of human skin with rubber protective gear | JOHNS HOPKINS UNIVERSITY | 2006-04-20 | — | — | US | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005087099-A2 | METHODS AND DEVICES FOR IDENTIFYING TERRORISTS/CRIMINAL SUSPECTS BY DETECTING CONTACT OF HUMAN SKIN WITH RUBBER PROTECTIVE GEAR | JOHNS HOPKINS UNIVERSITY (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | CYP3A4 987/4885CYP2C9 1835/4885HTR2C 1006/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | CYP3A4 987/4885CYP2C9 1835/4885HTR2C 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.